新型表面涂层可帮助糖尿病患者植入物更好地与骨骼结合
New surface coating could help implants bond better with bone in people with diabetes
弗林德斯大学研究人员开发了一种新的表面涂层技术,旨在改善糖尿病患者植入物与骨骼的结合。研究发现,高级糖基化终产物(AGEs)会附着在植入物表面并引发炎症反应,妨碍新血管和健康组织的形成。新技术通过表面工程减少AGEs的附着,促进更好的生物反应。
研究揭示了糖尿病患者植入物与骨组织结合不良的原因,并提出了一种新的表面工程技术来改善这一问题。
Flinders University researchers are launching an innovative surface-engineering technology that could help to raise the performance of implantable medical devices in people with diabetes and other metabolic diseases.
People living with diabetes face increased risks of complications following medical implantation procedures, including impaired tissue integration, persistent inflammation and delayed healing.
The new advanced material coating aims to open opportunities for a new generation of safer, more effective implants—starting with orthopedic implants such as hip and knee replacements, and potentially dental implants, cardiovascular stents and other medical devices.
The international research team, led by scientists at the Flinders Biomedical Nanoengineering Laboratory, has based the technology on an advanced implant coating designed to counteract the biological mechanism that contributes to common complications in diabetic patients.
Published in the journal Advanced Science, the research reveals that "advanced glycation end-products" (AGEs)—or molecules that accumulate in diabetes and other metabolic conditions—can attach to implant surfaces and trigger harmful responses to implants.
Lead author Matthew Flinders Professor Krasimir Vasilev, professor of biomedical nanotechnology at Flinders University, says the discovery challenges conventional approaches to implant design.
"Medical implants are typically developed and evaluated under conditions that do not adequately reflect the biological environment of patients with chronic diseases such as diabetes," says Vasilev, director of the Flinders Biomedical Nanoengineering Laboratory.
"Our research demonstrates that the accumulation of AGEs on implant surfaces triggers inflammation that promotes fibrotic tissue formation and interferes with the formation of new blood vessels and healthy tissue integration. Importantly, we have shown that these detrimental responses can be substantially reduced by engineering the chemistry of the implant surface."
The new approach to implant design uses advanced plasma-based surface-engineering techniques to develop specialized coatings that resist AGE accumulation and promote a more favorable biological response.
In experimental models focused on diabetes, the modified implants reduced inflammatory responses and fibrotic encapsulation while promoting blood vessel formation and stronger integration with surrounding bone.
The findings come ahead of World Diabetes Day on Nov. 14, highlighting the importance of improving health care outcomes for the rapidly growing number of people living with diabetes.
The prevalence of diabetes is rising globally, and WHO reports that the number of people living with diabetes increased from 200 million in 1990 to 830 million in 2022—and as populations age, growing numbers of these patients require orthopedic, dental and other implantable medical devices.
The global implantable medical devices market size was valued at more than US$104.48 billion in 2025, and is projected to exceed US$179.38 billion by 2034.
Up to 20% of this market was linked to individuals with chronic conditions such as diabetes, where implant failure rates are markedly higher, says Vasilev, defining a possible market exceeding US$20 billion for advanced biomaterials-enabled devices capable of performing in hostile biological environments.
"Rather than simply developing materials that perform well in healthy patients, we are engineering implant surfaces to function in the challenging biological environments associated with disease.
"This represents a fundamentally different approach to biomaterials design, with the potential to improve implant performance in patient populations that are particularly vulnerable to complications."
Researchers say the technology could also be used for implantable devices used in patients with chronic kidney disease, cardiovascular disease and other conditions associated with elevated AGE levels and altered tissue responses—including tissue engineering constructs and other devices where long-term performance depends on successful interaction with surrounding tissues.
The plasma-based technology, which is supported by intellectual property protection, can be used on existing implant materials without changes to the underlying device.
"One important advantage of this approach is that it has a strong foundation for commercial translation," says Vasilev. "Manufacturers could potentially incorporate the specialized surface treatment into existing devices rather than redesign the entire implant."
Publication details
Thien Ngoc Le et al., Rational Surface Engineering Reduces Advanced Glycation End‐Product Adsorption and Improves Implant Integration, Advanced Science (2026). DOI: 10.1002/advs.78507
Journal information: Advanced Science
Clinical categories
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: New surface coating could help implants bond better with bone in people with diabetes (2026, November 9) retrieved 9 November 2026 from https://medicalxpress.com/news/2026-11-surface-coating-implants-bond-bone.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com